158 related articles for article (PubMed ID: 20127705)
1. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.
Fratta E; Sigalotti L; Colizzi F; Covre A; Nicolay HJ; Danielli R; Fonsatti E; Altomonte M; Calabrò L; Coral S; Maio M
J Cell Physiol; 2010 May; 223(2):352-8. PubMed ID: 20127705
[TBL] [Abstract][Full Text] [Related]
2. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
4. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
Coral S; Parisi G; Nicolay HJ; Colizzi F; Danielli R; Fratta E; Covre A; Taverna P; Sigalotti L; Maio M
Cancer Immunol Immunother; 2013 Mar; 62(3):605-14. PubMed ID: 23138873
[TBL] [Abstract][Full Text] [Related]
6. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
8. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.
Kim KH; Choi JS; Kim IJ; Ku JL; Park JG
World J Gastroenterol; 2006 Sep; 12(35):5651-7. PubMed ID: 17007017
[TBL] [Abstract][Full Text] [Related]
10. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
11. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
12. Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells.
Bert T; Lubomierski N; Gangsauge S; Münch K; Printz H; Prasnikar N; Robbel C; Simon B
Pancreatology; 2002; 2(2):146-54. PubMed ID: 12123095
[TBL] [Abstract][Full Text] [Related]
13. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.
Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2008 Apr; 14(7):1984-96. PubMed ID: 18381936
[TBL] [Abstract][Full Text] [Related]
15. Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.
Xie C; Subhash VV; Datta A; Liem N; Tan SH; Yeo MS; Tan WL; Koh V; Yan FL; Wong FY; Wong WK; So J; Tan IB; Padmanabhan N; Yap CT; Tan P; Goh LK; Yong WP
Cell Oncol (Dordr); 2016 Apr; 39(2):175-86. PubMed ID: 26868260
[TBL] [Abstract][Full Text] [Related]
16. Alternative promoters of gene MAGE4a.
De Plaen E; Naerhuyzen B; De Smet C; Szikora JP; Boon T
Genomics; 1997 Mar; 40(2):305-13. PubMed ID: 9119398
[TBL] [Abstract][Full Text] [Related]
17. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
18. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
[TBL] [Abstract][Full Text] [Related]
20. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.
Kondo T; Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2007 Aug; 13(16):4713-20. PubMed ID: 17699848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
